Clinical trialPhase 1Not yet recruiting
Treating Nectin-4-positive Advanced Solid Tumors With R-Star001 (Nectin-4-CART-IL18)
A Single-center, Single-arm, Dose-escalation Exploratory Clinical Trial on the Safety, Efficacy, and Pharmacokinetics of R-Star001 Cell Injection in Patients With Nectin-4-positive Advanced Solid Tumors
- Outcome
- Ongoing
- Cell product
- CAR-T cells
Treating Nectin-4-positive Advanced Solid Tumors With R-Star001 (Nectin-4-CART-IL18)
- Target antigen
- Nectin-4
Treating Nectin-4-positive Advanced Solid Tumors With R-Star001 (Nectin-4-CART-IL18)
- Phase
- Phase 1
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- 1 August 2025
- Expected end
- 1 August 2028
- Enrollment
- 25 participants
- Sites
- 1
- Primary outcomes
- Dose limiting toxicity (DLT); Adverse events (AEs); Maximum tolerated dose (MTD)
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 3 August 2025
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
A single-center, single-arm, dose-escalation exploratory clinical trial on the safety, efficacy, and pharmacokinetics of R-Star001 cell injection in patients with Nectin-4-positive advanced solid tumors.
Detailed description public domain (ClinicalTrials.gov)
This study is a prospective, single-center, single-arm, open-label, single-dose administration dose-finding study, which aims to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy characteristics of the R-Star001 cell injection in subjects with Nectin-4 positive advanced solid tumors. The study will enroll subjects with pathologically confirmed advanced solid tumors (including, but not limited to breast cancer, urothelial carcinoma, colorectal cancer, head and neck squamous cell carcinoma, ovarian cancer, esophageal cancer, lung cancer) who have failed standard therapy; AND immunohistochemical analysis of histological or cytological tumor specimens demonstrates moderate to high Nectin-4 expression. This prospective, single-center, single-arm, open-label study employs a single-dose administration design across two sequential stages. Stage 1 (Dose Escalation) utilizes an accelerated titration approach with standard '3+3' dose escalation to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of R-Star001 Cell Injection in subjects with Nectin-4 positive advanced solid tumors, thereby determining expansion dose levels based on integrated cohort data. Stage 2 (Dose Expansion) will enroll up to 9 subjects per cohort (including escalation-phase subjects) at 1-2 selected dose levels to further characterize safety and efficacy. The Recommended Phase II Dose (RP2D) will be determined post-infusion through comprehensive analysis of Stage 1 safety/efficacy outcomes, pharmacokinetic profiles, and prior preclinical/clinical evidence. Main purpose: the safety and tolerability of R-Star001 cell injection in patients with Nectin-4 positive advanced solid tumors, and determine the Recommended Phase II Dose (RP2D). Secondary Purpose: The pharmacokinetic and pharmacodynamic characteristics of R-Star001 cell injection in patients with Nectin-4 positive advanced solid tumors; To preliminarily evaluate the efficacy of R-Star001 cell injection in patients with Nectin-4 positive advanced solid tumors. Evaluate the immunogenicity of R-Star001 cell injection.
Intervention public domain (ClinicalTrials.gov)
Drug: R-Star001. Drug: Nectin-4-targeted CAR T-cell injection with inducing IL-18 secretion (R-Star001). The trial consists of a traditional '3 + 3' pattern dose-escalation phase and a dose-expansion phase.
Arm public domain (ClinicalTrials.gov)
Nectin-4-targeted CAR T-cell injection with inducing IL-18 secretion (experimental): Experimental: Phase 1, open-label, single-arm trial. Drug: Nectin-4-targeted CAR T-cell injection with inducing IL-18 secretion.